Page 2 - போஸ்டர் ப்ரெஸெஂடேஶந்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from போஸ்டர் ப்ரெஸெஂடேஶந்ஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In போஸ்டர் ப்ரெஸெஂடேஶந்ஸ் Today - Breaking & Trending Today

PYC Therapeutics Announces Two Poster Presentations at Association for Research in Vision and Opthalmology (ARVO) 2021 Annual Meeting


PYC Therapeutics Announces Two Poster Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
PYC s PPMO Technology Demonstrates Strong Potential to Overcome Critical Delivery Challenges and Reach Deepest Layers of Retina in Patient-Derived Models
Modulation of Gene Expression to Upregulate PRPF31 and Rescue Retinitis Pigmentosa Type 11 Disease Phenotypes Achieved in Patient-Derived Models
News provided by
Share this article
Share this article
NEW YORK and PERTH, Australia, May 4, 2021 /PRNewswire/  PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the Company has been invited to present two poster presentations at the Association for Research in Vision and Opthalmology (ARVO) 2021 Annual Meeting, taking place virtually May 1–7, 2021. ....

Western Australia , Phosphorodiamidate Morpholino Oligomer , Janya Grainok , Group Leader , Association For Research , Professor Sue Fletcher , Chief Scientific Officer , Poster Presentations , Drug Delivery , Gene Therapy , Pyc Therapeutics , மேற்கு ஆஸ்திரேலியா , குழு தலைவர் , சங்கம் க்கு ஆராய்ச்சி , ப்ரொஃபெஸர் வழக்கு பிளெட்சர் , தலைமை அறிவியல் அதிகாரி , போஸ்டர் ப்ரெஸெஂடேஶந்ஸ் , மருந்து டெலிவரி , கீந் சிகிச்சை , பய்க் சிகிச்சை ,

Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting


Search jobs
30-Apr-2021
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
 
SYDNEY, AUSTRALIA – 29 April 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June. ....

Western Australia , United States , Israel General , New South Wales , Frankfurt Am Main , Comunidad Autonoma De Cataluna , Klinische Krebsforschung , Irene Brana , Krankenhaus Nordwest , Tim Clay , Thorsten Oliver Goetze , Immutep Limited , American Society Of Clinical Oncology , Australian Securities Exchange , University Cancer Center Frankfurt , Merck Co Inc , Merck Kga , Pfizer Inc , Hebron Institute Of Oncology , Institute Of Clinical Cancer Research , Merck Kgaa , Immutep To Announce New , Poster Presentations , American Society , Clinical Oncology , Poster Session ,

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting


Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
April 27, 2021 17:47 ET
| Source:
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Novato, California, UNITED STATES
NOVATO, Calif., April 27, 2021 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturing data from its investigational gene therapy programs will be presented at the American Society of Gene & Cell Therapy (ASGCT) 24
th Annual Meeting, which will be held virtually May 11-14, 2021.
“We continue to advance our proprietary HeLa producer cell line (PCL) manufacturing platform and look forward to sharing recent HeLa 3.0 improvements that further increase producti ....

University Of Pennsylvania , United States , United Kingdom , Joshua Higa , Nicholas Richards , Barbaraa Sullivan , Sam Wadsworth , Caryo Harding , Davidf Rodriguez Buritica , Lili Wang , Ultragenyx Pharmaceutical Inc , Exchange Commission On , American Society Of Gene Cell Therapy , Exchange Commission , University Of Texas Mcgovern Medical School , Oregon Health Science University , American Society , Cell Therapy , Annual Meeting , Chief Scientific Officer , Ultragenyx Gene , Ornithine Transcarbamylase , Potential Treatment , Late Onset Ornithine Transcarbamylase , Updated Results , Oregon Health ,